Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis

Journal of Chemotherapy

Volumn 22, Issue 2, 2010, Pages 119-124

  Zhao, Hui ^a   Yao, Yang ^a   Wang, Zhiyu ^a   Lin, Feng ^a   Sun, Yuanjiu ^a   Chen, Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Lung metastasis; Osteosarcoma; Pirarubicin

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; IFOSFAMIDE; MESNA; ONDANSETRON; PIRARUBICIN;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; DEPRESSION; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OSTEOSARCOMA; OVERALL SURVIVAL; PERIPHERAL NERVE TOXICITY; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCHOOL CHILD; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77951517908     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.2.119     Document Type: Article

References (14)

1. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome ol patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21(10): 2011-2018.
2. Meyer WH, Pratt CB, Poquette CA, Rao BN, Parham DM, Marina NM. et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 2001; 19(1): 171-182.
3. Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, Asada N, Abe S, Iso K, Sugita T, et al. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol 2002; 20 (16): 3470-3477.
4. Sridhar KS, Hussein AM, Benedetto P, Ardalan B, Savaraj N, Richman SP. Phase II trial ol 4 -O-tetrahydropyranyladriamycin (Pirarubicin) in head and neck carcinoma. Cancer 1992; 70 (6): 1591-1597.
5. Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 2007; 25 (3): 107-114.
6. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, et al. Phase II clinical and pharmacological sludy of piracubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res 1995; 1 (7): 691-697.
7. Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, et al. Metastatic osteosarcoma, results of two consecutive therapeutic trials at St. Jude Children's Research hospital. Cancer 2006; 106 (2): 403-412.
8. Koh E, Ueda Y, Nakamura T. Kobayashi A, Katsuta S, Takahashi H. Apoptosis in young rats with adriamycin-induced cardiomy-opathy-comparison with pirarubicin, a new anthracycline derivative. Padiatr Res 2002; 51 (2): 256-259.
9. Chenghui Huang; Zhaoxia Xie. Comparison of the inhibition on K562/A02 cell lines by Adriamycin and Pirarubicin in vitro. Chinese Journal of Hematology 2005; 26(5): 311-312.
10. Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K. Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother 2002; 36 (6): 996-999.
11. O'Connor R.. The pharmacology of cancer resistance. Anticancer Res 2007; 27 (3A): 1267-1272
12. Mahadevan D, Shirahatti N. Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies. Curr Cancer Drug Targets 2005; 5 (6): 445-455.
13. Martin-Richard M, Muñoz M, Albanell J, Colomo L, Bellet M, Rey MJ, et al. Serial topoisomarase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 2004; 66 (5): 388 94
14. Nagai K, Nagasawa K, Sadsuka Y, Tsujimoto M, Takara K. Ohnishi N, et al. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol 2002; 49 (3): 244-250.